|
Comparative Effectiveness Research Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CMS, FDA
|
OD/OSP, CC, CSR, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP
|
The NIH Comparative Effectiveness Research Coordinating Committee (CER CC) was established in 2008 at the request of the NIH Director. Its members include NIH Institute and Center (IC) Directors and high level senior staff. Its charge is to coordinate ongoing CER initiatives across the agency, develop a long term research vision for CER, implement collaborative initiatives with sister agencies, determine appropriate definitions, policies and guidance relative to CER, administer the CER funds awarded through ARRA, and track the outcomes of those projects. The CER CC has organized meetings with AHRQ, CMS, the VA, FDA, the Office of the National Coordinator for Health Information Technology (ONC), and PCORI, to discuss potential strategic collaborations. NIH invested $597M in CER in FY2012, and estimates funding $581M in FY 2013.
|
|
Comparison of Age-Related Macular Degeneration (AMD) Treatment Trials
|
Research Initiative
|
CMS
|
NEI
|
Head-to-head Comparative Effectiveness Trial between two chemically related ant-VEGF treatments for Age-related Macular Degeneration
|
|
Computational Toxicology for NIH Medications Discovery
|
Research Initiative
|
FDA
|
NIDA
|
Through an inter-agency agreement, the FDA provides structure-activity, relationship-based toxicity predictions for compounds that are under evaluation in the NIDA Addiction Treatment Discovery Program. On a limited basis, other NIH ICs may utilize this resource by working through NIDA.
|
|
Computer-aided Diagnosis for Radiology Images
|
Research Initiative
|
FDA
|
CC
|
The collaboration focuses on the improvement of computer-aided diagnosis for radiology images. Specific applications include computer-aided polyp detection for CT colonography, improvements in the conduct and analysis of observer performance experiments using radiology images and the use and development of advanced machine learning and receiver operating characteristics methods with application to computer-aided diagnosis.
|
|
Conducting Comprehensive Toxicological Assessments
|
Research Initiative
|
FDA
|
NIEHS
|
The purpose of this Agreement is to conduct, at FDA/NCTR, comprehensive toxicological assessments on FDA priority chemicals/agents nominated to the National Toxicology Program. Studies can include range finding sub-chronic and chronic, compound-specific mechanistic studies, and consideration of the use of alternate test systems. This combination of studies is designed to facilitate the interpretation of study results in support of comprehensive quantitative human health risk assessments. The primary goal of this program is to develop a comprehensive scientific data base that can be utilized to reduce the uncertainty in risk assessment/risk benefit analysis for specific chemicals with high FDA impact.
|
|
Congenital Heart Disease Expert Meeting
|
Meeting/ Workshop
|
CDC
|
NHLBI
|
The goal of this CDC-sponsored meeting was to develop a public health research agenda for congenital heart disease. An NHLBI representative participated on the committee with CDC members that planned and oversaw the meeting. Fifty invited experts attended the meeting representing diverse expertise in content (congenital heart disease, adult heart disease, statistics), methods (public health strategies), and personal experience. The group included persons from varied backgrounds (physicians, surgeons, epidemiologists, public health officials, advocates, and patients), with a broad representation of public health, professional, and Congenital Heart Disease (CHD) advocacy organizations. The meeting focused on four specific areas including epidemiology, health services, long term morbidity and mortality, and long term psychosocial and neurodevelopmental outcomes. The findings from the meeting were summarized in a manuscript which will be published in a cardiology or public health journal.
|
|
Congenital Heart Public Health Consortium
|
Resource Development
|
AHRQ, CDC
|
NHLBI
|
The Congenital Heart Public Health Consortium (CHPHC) is a group of organizations uniting resources and efforts in public health activities. The mission of the CHPHC is to prevent congenital heart defects and improve outcomes for affected children and adults. The consortium achieves its mission by providing leadership and a unified voice for public health priorities, expanding opportunities for surveillance and public health research, and informing public policy priorities that benefit public health and affected persons. The CHPHC represents various federal, state, and community organizations, including those representing patient/family, clinical, and research interests. It is pooling expertise and experience and using a public health model to address Congenital Heart Disease (CHD) issues across the lifespan.
|
|
Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus
|
Meeting/ Workshop
|
AHRQ
|
OD/DPCPSI/ODP, NICHD
|
Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during the third trimester of pregnancy). In collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the NIH Office of Disease Prevention organized a Consensus Development Conference to better understand the benefits and risks of various GDM screening and diagnostic approaches. After weighing the evidence presented by speakers and an evidence report, an unbiased, independent panel prepared and presented a consensus statement addressing the key questions. The conference was held on March 4-6, 2013.
|
|
Consortium for TB Biomarkers (CTB2)
|
Research Initiative
|
FDA
|
NIAID
|
The CTB2 seeks to establish a robust biorepository of well-documented clinical specimens to support the discovery and qualification of biomarkers of TB drug effect, especially surrogate markers for stable cure vs. relapse, and to facilitate development of rapid, reliable TB diagnostics, including tests for drug-susceptibility that would be practical for use in resource poor settings.
|
|
Council on Emergency Medical Care
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CMS, HRSA, OS
|
NIMH, NHLBI, NICHD, NINDS, NLM
|
The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers in emergency medical care from organizations across the Federal Government. The CEMC provides strategic and operational support to the HHS Emergency Care Coordinating Committee (ECCC) through policy-level guidance and interdepartmental and interagency collaboration for ongoing and future Federal efforts that address daily emergency medical care issues in the US. This entity contributes to the development, advancement, and coordination of Federal strategies, policies, and priorities relating to emergency medical care to improve the nation''s emergency care system.
|